Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy - Takeaways - MDSpire

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

  • By

  • Peter May

  • Christof Winter

  • Inga Hubrecht

  • Adrian Patenge

  • Selina Strathmeyer

  • Roland Geyer

  • Steffen Heelemann

  • Jan Stratmann

  • Seyer Safi

  • Henriette Klein

  • Folker Schneller

  • Florian Bassermann

  • Aaron Becker von Rose

  • May 18, 2026

  • 0 min

Share

  • 1

    Serum metabolomic profiles can predict clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients receiving pembrolizumab and chemotherapy.

  • 2

    Lower levels of branched-chain amino acids (BCAAs) like valine and isoleucine are linked to disease progression within 60 days.

  • 3

    Long-term survivors exhibited higher serum levels of specific lipids, including total phospholipids and apolipoproteins A1 and A2.

  • 4

    Higher inflammatory markers, such as glycoprotein acetyls, were associated with patients who died during follow-up.

  • 5

    A Random Forest model achieved high accuracy (AUC = 0.93) in predicting survival status based on metabolomic data.

Original Source(s)

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

  • by Peter May, Christof Winter, Inga Hubrecht, Adrian Patenge, Selina Strathmeyer, Roland Geyer, Steffen Heelemann, Jan Stratmann, Seyer Safi, Henriette Klein, Folker Schneller, Florian Bassermann, Aaron Becker von Rose

  • May 18, 2026

Related Content

Case report: Helical tomotherapy-based whole lung irradiation with simultaneous integrated boost for pulmonary metastatic Ewing’s sarcoma: a case series report and feasibility analysis

County-Level Structural Racism Indices and Racial Disparities in Lung Cancer Care

Synchronous lung adenocarcinoma in situ and type B2-B3 thymoma in a frozen hemithorax: a case report and multidisciplinary approach